AUS
NZ
UK
CA
USA
IND
Highlights
- The Australian Competition and Consumer Commission (ACCC) approves Sigma Healthcare’s merger with Chemist Warehouse Group (CWG), with conditions.
- Sigma to acquire CWG for shares and $700m in cash, resulting in Chemist Warehouse shareholders holding 85.75% of the merged entity.
- ACCC finds that the merger will not substantially lessen competition due to the presence of other major wholesalers.
- Sigma commits to ensuring pharmacies under long-term contracts can exit without undue cost and protecting their data.
- The merged entity will continue fulfilling the Community Service Obligations for five years.
Sigma Healthcare (ASX:SIG) has taken a major step toward completing its merger with Chemist Warehouse Group (CWG), following the Australian Competition and Consumer Commission’s (ACCC) decision not to oppose the deal. The merger, which will see Sigma acquire CWG in exchange for shares and $700 million in cash, marks a significant moment in the healthcare sector and is poised to create a major ASX-listed healthcare company.
The deal represents a reverse acquisition, with Chemist Warehouse shareholders set to own 85.75% of the combined entity post-merger. Sigma CEO Vikesh Ramsunder hailed the ACCC’s approval as a "critical milestone," emphasizing the merger's potential to create a stronger, more competitive player in the Australian healthcare market.
The ACCC's investigation into the merger found that the transaction is unlikely to substantially lessen competition in the wholesale pharmaceutical market. The regulator pointed out that the presence of other significant wholesalers, such as Australian Pharmaceutical Industries (API) and EBOS, along with the ability for pharmacies to switch suppliers, meant that competition would not be adversely affected.
To address any concerns about the merger’s impact, Sigma has provided a court-enforceable undertaking to ensure that pharmacies under long-term contracts will be able to exit these agreements without undue financial burden. Furthermore, the company will take steps to protect the data of these pharmacies as part of the agreement.
In addition, the merged entity has committed to upholding the Commonwealth Government’s Community Service Obligations for five years, ensuring the continued and equitable supply of Pharmaceutical Benefits Scheme (PBS) medicines to pharmacies across the country. This move reassures stakeholders that the essential services provided under the PBS will remain intact, even with the merger.
Following the ACCC's decision, Sigma’s stock saw a significant surge, with shares climbing 32.65%, reaching $2.58. This surge reflects investor confidence in the merger’s success and its potential to drive value for shareholders.
